<DOC>
	<DOCNO>NCT02094534</DOCNO>
	<brief_summary>This prospective , randomize , double-blind , placebo control study . Patients establish Type 1 diabetes eligible entry study . Eligible patient screen fulfill inclusion/exclusion criterion admit inpatient unit few 2 day 7 day Screening . Patients report inpatient unit 6 a.m. outfit continuous glucose monitoring ( CGM ) device . Patients give standardized meal snack duration inpatient visit .</brief_summary>
	<brief_title>A Prospective , Randomized , Double-blind , Placebo Controlled Study Assess Impact ORMD-0801 ( Insulin Capsules ) Exogenous Insulin Requirements Type 1 Diabetics</brief_title>
	<detailed_description>For first 3 day , patient dose placebo 45 minute prior day 's 3 meal establish baseline insulin requirement . Patients dose exogenous insulin accord normal slide scale patient 's daily insulin requirement document . The average daily insulin requirement 3 day run-in period constitute patient 's baseline insulin level . Following 3 day run-in , CGM device detach , data download , patient refit CGM fresh cannula continue monitor 7-day treatment period . Patients randomize 2:1 receive ORMD-0801 placebo 7-day double-blind treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Males Females age 18 55 year old , inclusive . Patients must willing able sign inform consent . Documented history Type 1 Diabetes least 6 month Females childbearing potential must negative serum pregnancy test screen negative urinary screen test follow admission inpatient unit Presence clinically significant endocrine disease accord Investigator ( euthyroid patient replacement therapy include dosage thyroxine stable least six week prior Screening ) Fasting plasma glucose &gt; 260 mg/dL end runin Evidence unawareness hypoglycemia document plasma glucose ≤50 mg/dL absence symptom hypoglycemia Presence clinically significant condition might interfere evaluation study medication ( i.e. , significant renal , hepatic , gastrointestinal ( GI ) , cardiovascular ( CV ) , immune disease ) . Presence history cancer within past five year exception adequatelytreated localized basal cell skin cancer situ uterine cervical cancer Laboratory abnormality screen include : Positive pregnancy test female childbearing potential ( screen Day 3 Visit 2 ) Abnormal serum thyrotropin ( TSH ) level &gt; 1.5X upper limit normal ( ULN ) Positive test hepatitis B surface antigen and/or hepatitis C antibody Positive test HIV Any relevant abnormality interfere efficacy safety assessment study drug administration Use follow medication : History use aprotinin time prior screen visit ( e.g. , Trasylol , type dose ) Administration thiazolidinedione [ e.g. , ( Actos ( pioglitazone ) Avandia ( rosiglitazone ) ] treatment within 3 month prior randomization . Administration thyroid preparation thyroxine ( except patient stable replacement therapy ) within 6 week prior screen visit Administration systemic longacting corticosteroid within two month prolong use ( one week ) systemic corticosteroid inhale corticosteroid ( daily dosage &gt; 1,000 μg equivalent beclomethasone ) within 30 day prior screen visit Use medication know modify glucose metabolism decrease ability recover hypoglycemia oral , parenteral , inhaled steroid ( discuss ) , beta blocker ( exception beta blocker ophthalmic solution glaucoma ocular hypertension ) , immunosuppressive immunomodulating agent History severe multiple allergy , know allergy soy aprotinin . History tobacco nicotine use within 10 week prior screen Patient weight loss program maintenance phase , patient start weight loss medication ( e.g. , orlistat sibutramine ) within 8 week prior screen Pregnancy breastfeed Patient screen visit systolic blood pressure ≥165 mmHg diastolic blood pressure ≥100 mmHg . Patient , time consent , user recreational illicit drug recent history ( within last year ) drug alcohol abuse dependence . ( Note : Alcohol abuse include heavy alcohol intake define &gt; 3 drink per day &gt; 14 drink per week , binge drinking ) Elevated liver enzyme ( alanine transaminase ( ALT ) , alanine aminotransferase ( AST ) , alkaline phosphatase ) great 2 time upper limit normal ( ULN ) Screening Very high triglyceride level ( &gt; 600 mg/dL ) Screening Any clinically significant electrocardiogram ( ECG ) abnormality screen cardiovascular disease . Clinically significant cardiovascular disease include : history stroke , transient ischemic attack , myocardial infarction within 6 month prior screen , history currently New York Heart Associate Class IIIV heart failure prior screening , uncontrolled hypertension define ( duplicate seat reading ) blood pressure ≥165 mmHg ( systolic ) ≥100 mmHg ( diastolic ) screen Visit 2 . History gastrointestinal disorder ( e.g . hypochlorhydria ) potential interfere drug absorption At Principal Investigator 's discretion , condition factor deem unsuitable patient enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Diabetes type 1</keyword>
	<keyword>Oral Insulin</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Phase 2a</keyword>
	<keyword>Randomized</keyword>
	<keyword>Blinded</keyword>
	<keyword>Parallel</keyword>
</DOC>